WID’s Kris Saha was among UW–Madison researchers who have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.
WID’s Kris Saha spoke to Wisconsin Public Radio to answer questions about gene editing technology CRISPR in response to a question received by WHYsconsin.
The the MS Biotechnology program at UW and the Wisconsin Institute for Discovery are partnering to screen the documentary film “Human Nature”, an exploration of gene editing and its implications both biological and ethical.
WID’s Krishanu Saha and colleagues J. Benjamin Hurlbut and Sheila Jasanoff write in Scientific American about germ line editing and the need for more scientific and moral clarity.
An interdisciplinary pair of WID researchers has developed a new nanocapsule delivery method for delivering the CRISPR-Cas9 gene editing tool. The new system could be used for many types of gene therapies.
WID’s Randolph Ashton, assistant professor of biomedical engineering, is the new associate director for UW–Madison’s Stem Cell and Regenerative Medicine Center.
The Wisconsin State Journal, as part of its feature highlighting stem cell research at UW 20 years after James Thomson’s discovery, highlights WID researchers Randolph Ashton and Kris Saha.
A second WID-led team joins NIH’s Somatic Cell Genome Editing Consortium with a grant to study new methods of delivering the CRISPR/Cas9 system to the brain.
UW researchers led by WID’s Kris Saha join the National Institutes of Health’s Somatic Cell Genome Editing Consortium with a major collaborative award.
Investigators from WID are among the recipients of the latest round of UW2020 awards.
Error rates as high as 50 percent are a problem when the goal is to correct typos in the DNA that cause genetic disease. Now, a team of researchers led by WID’s Kris Saha has made the fix less mistake-prone.
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.